Abstract. cDNA microarray-based CGH (Microarray-CGH) is a useful technique for detecting genomic aberrations with a high resolution. However, the criteria for determining a genomic alteration have not been determined. We evaluated the genome-wide measurement of copy number of each gene in normal gastric and placenta tissues with both sex-matched, direct and sex-mismatched, indirect designs using 17K cDNA microarray. The results revealed the range of genomic copy number of normal tissues to be ±0.3 of the log 2 ratio (gain >0.3, loss <-0.3) in the autosomal genes with direct and indirect designs. The copy number at a gene level from the X chromosomal genes using the direct and indirect sex-mismatched designs was ±0.68 of the log 2 ratio (amplification >0.68, deletion <-0.68). In summary, the suggested method can be used as a guideline for analysis of genomic aberration using a Microarray-CGH in both direct and indirect designs.
Introduction
Conventional comparative genomic hybridization (CGH) is used to analyze chromosome regional variations such as DNA gain, loss, amplification and deletion (1) . This technique can provide critical insights concerning the genomic instability and the nature of the sequences that can facilitate a chromosomal rearrangement. However, the low spatial resolution of 5-10 Mb is a caveat for conventional CGH. A screening method with a higher resolution, a bacterial artificial chromosome (BAC) array-based CGH was developed to reliably detect genome-wide deletions and amplifications (2, 3) . Because the BAC array-based CGH still has a limitation on a specific gene level, an innovative technique, a cDNA microarray-based CGH (Microarray-CGH), was developed (4) . A genomic alteration detected by Microarray-CGH can easily be translated into both sequence and gene identification, which can provide additional information concerning the complex chromosomal rearrangements and imbalances (5) .
Generally, array-based CGH has two types of experimental design for direct and indirect comparisons. The direct design compares a test sample with its paired reference sample (2, 6) , whereas the indirect design compares a test sample with a common reference, such as normal lymphocyte (7) (8) (9) (10) (11) or a normal placenta (12, 13) . Generally, the lymphocyte and placenta are presumed to be genomically normal and easy to obtain as a reference. However, with the indirect design, considerations must be paid to the organ-specific genomic difference between the test and reference samples, as well as to the sex-specific differences such as a sex-matched (11, 13) or sex-mismatched comparison with reference (5, 7) .
Theoretically, the log 2 ratio with single copy change of each gene using Microarray-CGH is supposed to be 1.0. However, experimentally measured single copy change of genes showed wide variations. In a test using the sex chromosomal genes, a log 2 ratio range of 0.22-0.28 was suggested for a single copy change at a gene level (3, 4) . With the indirect design, a log 2 ratio range of 0.2-0.6 has been suggested for a single copy change level of gene (7, 8, 10, 12, 14, (18) (19) (20) (22) (23) (24) .
In this study, the optimal log 2 ratio of genomic alterations such as gain, loss, amplification and deletion were determined using a Microarray-CGH system with special considerations on an organ-specific genomic difference (indirect design) and a sex-specific genomic difference (direct and indirect design).
Materials and methods
Tissues and cancer cell lines. Twenty-three normal gastric tissues (11 male and 12 female cases) which located >10 cm away from a tumor were obtained from gastric cancer patients who had undergone surgery. The male and female placenta tissues were obtained after a normal delivery. The tissues were procured with informed consent from the patients after the approval of the Institutional Review Board of Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, for 12-24 h. The incubated products were boiled for 10 min at 100˚C to inactivate the enzymatic activity and then treated with the same amount of phenol/chloroform/isoamylalcohol (Gibco-BRL, Gaitherburg, MD, USA). The DNA in the supernatant was precipitated with 100% ethyl alcohol containing a 1/3 volume of 10 M ammonium acetate and 2 μl of glycogen. After rinsing with 70% ethyl alcohol, the DNA was dried at room temperature and then dissolved in ultra-pure water. The DNA concentrations were determined using a UVspectrophotometer (Hitachi Inc., Tokyo, Japan) and stored at -20˚C until needed.
Microarray-CGH. The Microarray-CGH was performed according to the Cancer Metastasis Research Center Yonsei University College of Medicine, Korea (CMRC) protocol (13) in various experimental design (Table I) . Briefly, 6 μg of the extracted genomic DNA was digested at 37˚C, for 2 h by DpnII (NEB, Beverly, MA, USA) and cleaned up using a QIAquick PCR purification kit (QIAgen, Dusseldorf, Germany) according to the manufacturer's instructions. Labeling was performed with Cy3-dUTP or Cy5-dUTP, using a Bioprime labeling kit (Invitrogen, CA, USA) and the unincorporated nucleotides were removed using a PCR purification Kit (QIAgen). The eluted probes were then mixed and supplemented with 30 μg of Human Cot-1 DNA (Gibco-BRL), 20 μg of poly-A RNA (Sigma), 100 μg of yeast t-RNA (Gibco-BRL), and 288 μl of a 1 M TE buffer (pH 8.0). This probe mixture was concentrated using a Microcon-30 (Amicon, Bedford, MA, USA). For the final probe preparation, 15.3 μl of 20X SSC (pH 8.0) and 2.7 μl of 10% SDS were added to the probe mixture to make a total volume of 90 μl. The probe was denatured by heating for 2 min at 100˚C and then applied to the 17K human cDNA microarray (CMRC-GenomicTree Co., Korea). The microarray was hybridized at 65˚C for 16 h in a hybridization chamber (GenomicTree Co., Korea) with the humidity maintained by 3.5X SSC. After hybridization, the slides were washed for 2-5 min in 2X SSC with 0.1% SDS, which was followed by 1X SSC with 0.1% SDS, 0.2X SSC. The slides were then rinsed twice with 0.05X SSC. After washing, the slides were spun dried at 600 rpm for 5 min.
Microarray imaging and analysis. The slides were scanned using a GenePix 4000B scanner (Axon Instruments, Foster City, CA, USA) and the TIFF images were analyzed with GenePix Pro 4.1 software (Axon Instruments). The foreground and background intensities of both Cy3 and Cy5 were calculated for each spot and exported into Genepix Array List (GAL) files.
Data pre-processing and normalization. 17K cDNA microarray contained the 15,723 unique genes with 17,664 spots and these unique genes were mapped for their chromosomal location using SOURCE (http://genome-www5.stanford.edu/cgi-bin/ source/sourceSearch) and DAVID (http://apps1.niaid.nih.gov/ david/). In order to obtain accurate results, unfavorable spots were removed according to the following criteria: a) spots with low foreground intensity (foreground/background intensity ratio <1 or foreground intensity <500), b) the spots with an unknown chromosomal location, and c) the spots with a different location between SOURCE and DAVID. The transformation of the intensity signal to a ratio was carried out using the log 2 red to green ratio (R/G). In order to correct the differences caused by labeling efficiencies, a within-slide global normalization was applied, which subtracted the median intensity ratio of the log 2 (R/G) from the log 2 -transformed data. The log 2 data were linked to the genomic information, such as the gene name, the GeneBank accession number, the number of the chromosomal location, and then mapped onto the position of each chromosome. The genomic aberration patterns were presented using CGH analyzer and Map Viewer using S-Plus 2000 (CAMVS, CMRC) software.
Determination of the genomic alteration with log 2 transformed data. Genomic alterations of a gain or loss of each gene were determined to be greater or lower than the absolute mean ± standard deviation (SD) of the gene values within the autosome and sex chromosome. With the sex-mismatched designs, the values from the X chromosomal genes were used to determine an amplification or deletion. The genomic alterations of an Table I . Designs of experiments for determining genetic alterations of X chromosome located genes. 
P, normal placenta tissue; G, normal gastric tissue; XX, female tissue; XY, male tissue.
amplification or deletion of each gene were determined to be greater or lower than the absolute mean ± SD of the gene values within the X chromosome in a sex-mismatched design. Finally, we selected the pseudo-alteration genes in autosomes, which genes showed a consistent genomic alteration pattern regardless of various experimental designs.
Fluorescence in situ hybridization for c-erbB-2 amplification.
c-erbB-2 gene status was determined by fluorescence in situ hybridization (FISH). Interphase nuclei of YCC-16 gastric cancer cells were hybridized with red fluorescent-labeled probes. HER-2/neu probe mix was consisted of a mixture of a Spectrum Green fluorophore-labeled-·-satellite DNA probe for chromosome 17 and a Spectrum Orange fluorophorelabeled DNA probe for the c-erbB-2 gene locus (17q11.2-q12) (Vysis PathVysion ® HER-2 DNA Probe Kit; Vysis Inc., Downers Grove, IL, USA). c-erbB-2 and chromosome 17 nuclear signals were counted under a microscope, which yielded the ratio of the copy numbers of the c-erbB-2 gene to chromosome 17 (19) .
Results

Determination of genomic alteration and gene copy number change in Microarray-CGH.
After the filtration, 13,808 genes remained, which included 9,161 genes with a known chromosomal location. The 9,161 genes composed of 8,923 autosomal and 238 sex chromosomal genes including 5 Y chromosome located genes and 233 X chromosome located genes.
In order to determine the criteria of the genomic aberration, 25 Microarray-CGH with normal tissue samples including both the direct sex-matched or sex-mismatched designs and the indirect sex-matched or sex-mismatched designs were performed (Table II) .
First, 8,923 autosomal genes were evaluated to determine the gain or loss value in a sex-matched design. An absolute mean ± SD value of autosomal genes was 0.3 log 2 ratio in 10 indirect sex-matched designs, which was similar to that of the direct designs. Using a total of 14 direct and indirect sexmatched designs, the mean ± SD value of 8,923 autosomal genes was 0.3 log 2 ratio. Based on these results, the chromosomal aberration was determined to be >0.3 log 2 ratio as a gain or <-0.3 log 2 ratio as a loss.
Next, 233 X chromosomal genes were evaluated to determine the criteria of the amplification or deletion in the sex-mismatched designs with the assumption of a single copy change of X chromosomal genes. Using direct sexmismatched design, the 233 X chromosomal genes showed mean log 2 ratios of 0.70 and -0.67 log 2 ratio (Fig. 1A) . Indirect sex-mismatched experiments showed similar genomic aberration compared to direct sex-mismatched design, 0.69 and -0.72 log 2 ratio (Fig. 1B and C) . Based on the change in the X chromosomal genes, the criteria of a copy change at a gene level was determined to be >0.68 log 2 ratio as an amplification or <-0.68 log 2 ratio as a deletion (Fig. 2) .
Distribution of genomic alterations in autosomal and sexchromosomal genes. In the direct design, 89% of the genes in both the autosomes and sex-chromosomes showed no change in the log 2 ratio. However, 11% of the genes showed genomic alteration patterns >0.3 or <-0.3 log 2 ratio and 1% of the genes showed a copy change pattern >0.68 or <-0.68 log 2 ratio (Fig. 3A and C) . In the 11 indirect sex-mismatched designs, the criteria of the autosomal genes were -0.3 to -0.3 log 2 ratio and similar to those of the direct sex-mismatched design. Genomic alteration criteria were found in 5.5% of the genes and 0.4% of the genes showed a copy number change pattern with >0.68 or <-0.68 log 2 ratio (Fig. 3B) . In contrast, 60% of Table II . Genetic alteration of autosomal and sex chromosomal genes based on experimental design. -------------------------------------------------------------------------------------------------- 
-----------------------------------------------------------------------------------------------------
ratio >0.68) ----------------------------------------------------
X Y Autosome X p-value Autosome X Y (n=8,923) (n=233) -
-----------------------------------------------------------------------------------------------------
P, normal placenta tissue; G, normal gastric tissue; XX, female tissue; XY, male tissue; SD, standard deviation; gain, log 2 ratio >0.3; loss, log 2 ratio <-0.3; amplification, log 2 ratio >0.68; deletion, log 2 ratio <-0.68. Figure 1 . Distribution of genomic alterations according to genomic location on the X chromosome. (A) In the sex-mismatched, direct design, most X chromosomal genes showed >0.3 or <-0.3 log 2 ratios and average genomic aberration value was ±0.68 log 2 ratio with placenta (▲, •) and gastric tissue (Δ, ‡). (B) X chromosomal genes with sex-mismatched, indirect design showed a genomic aberration patterns (▲, •) (P, placenta tissue; G, gastric tissue; XX, female; XY, male). (C) Sex-matched, indirect design showed no genomic aberration patterns with the average log 2 ratio of 0 (Δ, ‡) (P, placenta tissue; G, gastric tissue; XX, female; XY, male). , X chromosomal genes; XX, female; XY, male; * p<0.001.
X chromosomal genes showed a genomic alteration pattern, and among these genes, 15% of the genes showed a duplicate gene change patterns as expected (Fig. 3D) .
Genes with a pseudo-alteration pattern. Fifteen autosomal genes showed consistent copy number change patterns, such as gain or loss, regardless of the experiment design. Among the genes with this type of false copy number change pattern, pseudo-alteration pattern, 10 deleted genes showed an average log 2 ratio of -0.49 to -1.04 and 5 amplified genes showed an average log 2 ratio of 0.48 to -0.76. Among these genes, the chromosome 6 open reading frame 198 (GenBank accession number AI589117) gene showed the pseudo-alteration pattern of 84% frequency with the mean log 2 ratio of -0.68 (Table III) . Table III . Genes showing the pseudo-alteration patterns. Dual-specificity tyrosine-(Y)-p 0.48±0.14 9
The genes that showed consistent genetic aberration. Mean, average log 2 value with all experiments; SD, standard deviation; frequency, number of amplificated or deleted genes among 25 experiments; cytoband, chromosomal location.
chromosomal genes and (D) sex-mismatched X chromosomal genes. n, number of genes; grey, -0.3< log 2 ratio <0.3; , log 2 ratio >0.3 or log 2 ratio <-0.3; , log 2 ratio >0.68 or log 2 ratio <-0.68; , single copy changed genes with known function; , single copy changed genes with unknown function.
Comparison of Microarray-CGH and FISH analysis in YCC-16 gastric cancer cells. In Microarray-CGH, YCC-16
gastric cancer cells showed a genomic alteration patterns in 17 chromosome. Twenty genes locating on 17q11.2-17q21.3 showed a normal genomic pattern except two clones of cerbB-2 gene (Fig. 4A) . The amplified gene copy number change detected by Microarray-CGH was confirmed by FISH analysis (Fig. 4B ).
Discussion
Generally, the direct design is an ideal platform for analyzing a genomic alteration in cancer. However, as the test samples are not always available paired normal tissues in other diseases, an indirect design is applied even if this system has the risk of a genomic disparity due to test organ differences. In the indirect design of CGH, normal lymphocytes or placenta tissues have been used as a reference (7) (8) (9) (10) (11) . This study determined the cut-off value for genomic alterations such as a gain, loss, amplification and deletion in the Microarray-CGH system using a normal placenta as a reference and normal gastric tissues as the test sample with sex-matched and -mismatched designs.
Several reports have described the advantage of DNA copy number change using a cDNA microarray with a high resolution with 0.5-2 kb length and a high sensitivity (4, 13) . In previous studied reported that Microarray-CGH has a weak point with a 10-15% false positive rate on detection and amplification of single copy change genes in genomic DNA due to sensitivity and specificity of Microarray-CGH (4). Our cDNA microarray composed of a 0.5-2 kb length of cDNA which clones distributed a 50-100 kb length of genomic DNA. Theoretically, the log 2 ratio of a one copy change of gene is 1. However, this study obtained an absolute 0.68 log 2 ratio for the gene copy change. This difference between theoretical and experimental values might be due to technical issues as well as the different platforms used. First, an underestimation of the X chromosome located genes might result from the cross-hybridization of the probe with an autosomal or Y chromosomal genes due to the strong homology to the target sequence of the X chromosomal genes (15) . Second, a random fragmentation step for the genomic DNA processing produced fragments with different sizes in the same gene. This phenomenon might cause differences in the labeling efficiency, which might result in a fluorescence difference. Moreover, the fragmentation activity by the restriction enzyme of DpnII is blocked by CpG methylation (16) , which also induces a variation in the fragmentation efficiency. Third, labeled genomic DNA fragments are hybridized to arrays made from the individual DNA fragments that have been cloned from a reduced sequence, i.e. not a full length sequence (17) . Moreover, the reduced sequence of each gene increases the genomic homology with the other genes, which may finally cause an altered reproducibility of hybridization among the different institutions. Fourth, by definition, a gene amplification means that the whole sequence of the genes is duplicated, triplicated, or more. However, in biological situations, genomic changes occur as a sub-regional sequence insertion or a deletion of a gene. In some cases, the genomic alteration is caused by a point mutation, insertion and deletion, which might cause differences in the labeling and fluorescence signals. These types of experimental variations described above have different criteria in determining the genomic alteration in both the Microarray-CGH and conventional CGH.
And several genes showed a pseudo-alteration patterns, which might be related to the effect of the fluorescence such as a difference in the dye incorporation rate or the dye degradation rate. Even if some genes are closely located at the chromosome 6q21 and 19q13.3, the genes on 6q21 and 19q13.3 showed a normal genomic aberration patterns.
Despite there being several sources of the experimental variations, the Microarray-CGH system developed in this study showed the systemic advantages and reproducibility. There was no difference of experiment patterns in the autosomal level even with the tissue differences used (gastric versus placenta) and the design differences such as direct versus indirect and sex-matched versus sex-mismatched.
Comparison of Microarray-CGH and FISH analysis validated our Microarray-CGH system as highly sensitive and specific system. Actually, the false positive rate in detecting an amplified or deleted gene change in our systems was 0.4-1%, suggesting 99% specificity and reproducibility. These false positive genes might be caused by genetical variation with cDNA sequence homology and individual variation of sample and technical variations such as 0.1-0.2% batch variation or a difference in the restriction enzyme activity. When we investigated the false positive genes, 2/3 of the false positive genes showed sequence homology genes in different chromosomes and 1/10 showed sequence homology genes in the same chromosome (data not shown).
In conclusion, from systemic analysis, |0.68| log 2 ratio was suggested as a criteria of genomic alterations such as duplicated or deleted gene changes regardless of difference in design (direct, indirect, sex-matched, or sex-mismatched).
